Reviewed for legal accuracy by Gary Matthews, Solicitor · Last reviewed: June 2026 · Jurisdiction: Republic of Ireland

This information is for educational purposes only and does not constitute legal advice. Every case is different and outcomes vary. Consult a qualified solicitor for advice specific to your situation.

How do abnormal blood test results signal blood cancer in Ireland?

Blood cancers frequently announce themselves on a routine blood test before any lump or obvious symptom appears. A full blood count (FBC), a bone profile or a serum protein test can carry the first clue to myeloma, leukaemia or lymphoma. Many patients are followed for months with "just anaemia" or "a slightly raised protein" before anyone connects the result to a malignancy. The cancer was already present when the blood was drawn, so the result was a missed opportunity to act, not the cause of the disease.

Failures at this stage are common in Ireland. According to the State Claims Agency, of the diagnosis incidents reported on the national system across 2022 and 2023, 79.2% were reported as a delayed diagnosis, 52% were reported at the test or investigation stage of the process, and in 55% the cause was recorded as a step not performed when indicated.^[15] The Agency notes that some of the test-stage incidents involved sampling problems, such as labelling errors, rather than results that went unactioned. A blood result that is recognised but never followed up sits within the broader pattern these figures describe.

Each of the three main blood cancers tends to leave a recognisable signature. Myeloma classically produces the CRAB features, a grouping clinicians use to flag plasma-cell disease. Leukaemia often shows abnormal or immature white cells and unexplained changes across cell lines. Lymphoma can present with a raised lymphocyte count, a high lactate dehydrogenase (LDH) reading and night sweats or weight loss alongside an abnormal count.

What turns a clinical pattern into a legal question is simple. The information that should have prompted action already existed inside the system. When that information sits unread in an electronic inbox, or is noted and then filed without a plan, the failure is one of follow-up rather than diagnosis. That distinction shapes the whole claim, and it is why blood cancers deserve their own treatment separate from a missed scan or a misread biopsy.

Which blood cancers most often start this way? Myeloma, the acute and chronic leukaemias, and the lymphomas account for most of these scenarios. The National Cancer Registry Ireland records that non-Hodgkin lymphoma, leukaemia and multiple myeloma are the most commonly diagnosed blood cancers in the country.^[4] For the claim itself, the specific cancer matters less than the blood finding that was available and ignored.

The table below sets out the clinical-to-legal translation at the centre of this page. It links a specific blood finding to the cancer it may signal and to why a competent Irish clinician should have acted. The referral thresholds draw on the NCCP Haematology Referral Information Manual and published Irish hospital haematology guidance.^[2][5]

Thresholds are drawn from Irish national and hospital haematology guidance and are illustrative, not a substitute for clinical judgement in an individual case.

What is the Irish haematology referral standard, and why is it not the UK pathway?

Ireland routes suspected blood cancers through the NCCP haematology referral system, not the UK "two-week wait". This matters because much of the information a worried patient finds online describes the British NHS pathway, which does not apply here. The National Cancer Control Programme publishes a Haematology Referral Information Manual for adults that sets out national guidance on the conditions that should prompt referral and how urgently.^[2]

The Irish system prioritises referrals using Clinical Prioritisation Categories rather than a single fixed two-week target. Where acute leukaemia is suspected, the expected response is immediate. Published Irish hospital guidance directs that suspected acute leukaemia is discussed with the haematology team by telephone for same-day assessment.^[5] Less acute but still concerning findings, such as a persistent unexplained anaemia or a new paraprotein, are referred for specialist outpatient assessment.

One Irish-specific point catches people out. Haematology is not a Rapid Access Clinic specialty. Ireland runs rapid access clinics for lung, prostate, breast and melanoma, and a worried patient sometimes assumes a similar fast-track exists for blood cancers.^[6] It does not work that way. Blood cancer referrals go directly to haematology under the NCCP categories. The speed and route of a referral, and any failure in it, are judged against that national standard.

What should a competent GP or hospital clinician have done with a red-flag result? At a minimum, recognise the finding and place it in context with the patient's symptoms and previous counts. The clinician should then either investigate it properly in primary care or refer to haematology with the right urgency. A result that is filed without any of those steps is the failure this page is about. The relevant question is not whether the doctor felt busy, but whether the action taken matched what the Irish referral standard expects. For the related failure of not referring at all, see our page on failure to refer for cancer testing.

When does failure to act on a blood result become negligent?

Failure to act becomes negligent when no competent clinician, following accepted practice, would have left the result unactioned. Irish medical negligence uses the two-stage test from Dunne v National Maternity Hospital [1989] IR 91. A clinician is negligent if the course taken is one that no professional of equal status, acting with ordinary care, would have followed. The alleged failure must also be more than a matter of legitimate professional disagreement.^[1] Our page on how breach of duty is proven works through that test in detail.

Three patterns recur in blood cancer claims of this kind. The first is the "just monitor" result, where anaemia or a raised protein is noted and repeat tests are ordered without escalation, even as the abnormality persists. The second is the filed-and-forgotten result, where an abnormal count lands in an electronic inbox and is never reviewed, often during a locum's cover or a transfer of care. The third is the uncommunicated result, where the abnormality is recognised inside the system but never reaches the patient or their GP with a plan attached.

Can you claim if your GP said to "just monitor" the anaemia or abnormal proteins? Possibly, yes. Monitoring can be reasonable for a borderline finding with no other features. It becomes a problem when the result, or the trend across several tests, met a recognised referral threshold and was still not escalated. Whether the line was crossed depends on the specific numbers, the pattern over time and the symptoms recorded, judged against the Irish referral guidance.

A common defence deserves a direct answer. Defendants often argue that a single result was borderline or could have been reactive, meaning caused by infection or another benign process. That argument weakens when the abnormality persisted or recurred, when the blood film showed specific features, or when symptoms accompanied the result. Irish guidance is also clear that some findings do not warrant referral. A raised immunoglobulin level without a monoclonal band on electrophoresis is one example, so a credible claim turns on findings that genuinely met the threshold.^[2]

Where does legitimate monitoring end and negligence begin?

The line sits where the finding crosses a recognised referral threshold, not where monitoring feels convenient. Many paraproteins reflect a benign condition called monoclonal gammopathy of undetermined significance, or MGUS. Irish guidance records that MGUS progresses to myeloma at around 1% per year, a rate that stays steady, so watchful monitoring of a genuine low-level MGUS is accepted practice.^[2]

The defence weakens when the result was never a simple MGUS picture. A new paraprotein alongside the CRAB features, a rising or higher-level band, or a finding with anaemia, renal impairment or bone pain points toward myeloma rather than stable MGUS. The question for a claim is whether the recorded result and its trend sat inside safe monitoring, or had already crossed into a referable finding that was missed.

Who should be responsible, the laboratory, the GP or the hospital? The duty to act on a result rests with the clinician who ordered the test. Where a hospital outsources sample analysis, it cannot escape responsibility for acting on the result. The Supreme Court in Morrissey v Health Service Executive [2020] IESC 6 confirmed that the HSE owes a non-delegable duty of care to patients.^[7] Analytical mistakes inside the laboratory itself, such as a sample mix-up or a calibration error, are a different claim and belong on our pathology and laboratory errors page.

How can you tell whether your own result was mishandled? A few things in your history are worth checking. You may never have been told a blood test was abnormal, or you may have learned of it only when you later read your records. You may have been told to monitor a result, yet no repeat test or appointment was ever arranged. The same abnormality may appear on test after test, slowly worsening, with no referral. Any of these patterns suggests the result was not followed through as Irish guidance expects. It is worth raising with a solicitor who can obtain the records and check the timeline.

How do you prove the delay caused harm in a blood cancer claim?

Proving a breach is only the first hurdle, because Irish law also requires you to show the delay caused real harm. A patient must demonstrate, with independent expert evidence, that acting on the result sooner would have changed the treatment or the outcome. Blood cancers raise this question differently from solid tumours, where the usual argument is "stage shift", a cancer growing from an early to a later stage during the delay.

The stakes of timely treatment are measurable in Irish data. The National Cancer Registry Ireland reports a clear rise in five-year survival for blood cancers. It moved from 53% for cases diagnosed in 1994 to 2007, up to 67% for cases in 2008 to 2021. The Registry attributes that gain to advances in diagnosis and treatment.^[11] Survival of this kind depends on reaching the right treatment at the right time, which is exactly what a missed result can delay. An expert translates that general picture into the specific difference the delay made for one patient.

For blood cancers, the lost opportunity often takes other forms. Delay can cost eligibility for an autologous stem-cell transplant, force the use of more intensive or more toxic treatment regimens, or reduce the realistic prospect of long-term remission. In an acute leukaemia, the window can be very short, and even weeks of delay can matter. An expert haematologist maps where the patient was when the result was ignored and where timely treatment would have placed them.

How do you prove the delay made a myeloma or leukaemia worse? Through independent haematology evidence that reconstructs the lost treatment window. The expert reviews the ignored result, the disease biology and the treatment that timely referral would have allowed, then forms a view on the difference the delay made. This is detailed, contested work, and it is why these claims need specialist medical input rather than assertion.

Irish law treats the "loss of a chance" of a better outcome with caution. Damages for a lost or reduced prospect of recovery are recognised in principle. The Supreme Court in Philp v Ryan [2004] IESC 105 shows the courts approach this area carefully, and recovery is not automatic. This is more generous than the position in England. There, Gregg v Scott, itself a non-Hodgkin lymphoma case, denied recovery because the patient's survival chance had always been below 50%.^[13][8] Our page on loss of chance in cancer claims explains how that doctrine is applied. The honest position is that causation is the hardest part of these cases, and a careful firm tests it early rather than promising an outcome.

Can the hospital blame you for not coming back sooner? A common defence is that the patient missed a follow-up or did not return when symptoms continued. Under section 34 of the Civil Liability Act 1961, a court can reduce an award to reflect a patient's own share of the fault, known as contributory negligence.^[12] This reduces the award rather than ending the claim. A patient who was told the result was nothing to worry about, or who was never warned the follow-up was urgent, has a strong answer to that argument. Our page on causation in medical negligence looks at how this is weighed.

What are the time limits when results were filed but ignored?

The two-year clock usually runs from your date of knowledge, not from the day the blood was taken. If the limit ran from the blood draw, almost every missed-result claim would be barred before the patient learned anything was wrong. The limitation period for a personal injury claim in Ireland is two years less one day. It is set by the Statute of Limitations (Amendment) Act 1991, and was reduced from three years to two by section 7 of the Civil Liability and Courts Act 2004.^[3]

The date of knowledge is the pivot. Under the 1991 Act, time starts when you first knew, or ought reasonably to have known, three things. These are that you had a significant injury, that it was caused by the act or omission alleged to be negligent, and that the defendant was the person responsible.^[3] When a result was in the system but never communicated, that knowledge often arrives late, sometimes only at a later consultation or after you request your own records.

What is the time limit if blood test results were never communicated to you? Two years less one day from when you reasonably should have known the result was missed and that it caused harm. Because discovery is frequently delayed in these cases, the gap between the ignored test and the start of the clock can be long. That is often a relief to someone who assumes they are already out of time because the test was years ago. Our pages on date of knowledge time limits apply this rule to common situations.

Two exceptions are worth noting. Where the injured person is a child, the period does not begin until their eighteenth birthday, though a parent or guardian can bring a claim earlier. Where a person lacks capacity, the period is paused for the duration of that incapacity. Time limits are strict and the analysis is fact-specific, so early advice protects your position. Pursuing this is part of bringing a personal injury claim in Ireland, and the deadline is the first thing a solicitor will check.

What may a blood cancer negligence claim include?

A successful claim compensates the harm the delay caused, not the cancer itself. Irish general damages for pain and suffering are assessed using the Personal Injuries Guidelines (2021), which replaced the older Book of Quantum. Awards are also subject to a general damages ceiling. Every award depends on the individual facts, and the Guidelines guide rather than dictate the figure in a clinical case.^[9]

A claim may cover the additional pain and suffering caused by a more advanced disease or more aggressive treatment. It can also cover the financial losses that flow from the delay, such as lost earnings and care costs, and the cost of treatment that timely diagnosis might have avoided. Where the harm is severe, future losses are also considered. We do not estimate figures online, because a credible figure depends entirely on the evidence in your case.

Most medical negligence claims of this kind proceed differently from a standard personal injury claim. They are generally exempt from the Injuries Resolution Board process under section 3(d) of the PIAB Act 2003. These claims proceed directly through the courts, in the High Court's clinical negligence list.^[10] That dedicated list was formalised by Practice Directions HC131 and HC132 from 28 April 2025, which also bring earlier mediation into these cases.^[14] Our page on cancer misdiagnosis compensation amounts explains how these claims are valued in practice.

Common questions about ignored blood test results and blood cancer

Related questions

References

1. Dunne v National Maternity Hospital [1989] IR 91, Supreme Court of Ireland (the two-stage test for clinical negligence). Court judgments database: courts.ie. Accessed June 2026.
2. National Cancer Control Programme, Haematology Referral Information Manual (Adult), HSE. healthservice.hse.ie. Accessed June 2026.
3. Statute of Limitations (Amendment) Act 1991 (date of knowledge test) and Civil Liability and Courts Act 2004, s.7 (limitation reduced to two years, commenced 31 March 2005). irishstatutebook.ie. Accessed June 2026.
4. National Cancer Registry Ireland, Cancer Trends No. 41: Haematological Malignancies (annual average 2,392 blood cancer cases, 9.8% of 24,424 invasive cancers, 2019 to 2021). ncri.ie. Accessed June 2026.
5. St Vincent's University Hospital, Haematology Department Referral Guidance (October 2023). stvincents.ie. Accessed June 2026.
6. Health Service Executive, Rapid Access Clinics for lung, prostate, breast and melanoma (NCCP). hse.ie. Accessed June 2026.
7. Morrissey v Health Service Executive [2020] IESC 6 (the HSE owes a non-delegable duty of care). courts.ie. Accessed June 2026.
8. Philp v Ryan [2004] IESC 105, Supreme Court of Ireland (loss of chance and the courts' approach). courts.ie. Accessed June 2026.
9. Judicial Council, Personal Injuries Guidelines (2021). judicialcouncil.ie. Accessed June 2026.
10. Personal Injuries Assessment Board Act 2003, s.3(d) (exemption of claims arising out of a medical or surgical procedure from the Injuries Resolution Board process). irishstatutebook.ie. Accessed June 2026.
11. National Cancer Registry Ireland, Cancer Trends No. 41: Haematological Malignancies (five-year survival for blood cancers rose from 53% in 1994 to 2007 to 67% in 2008 to 2021). ncri.ie. Accessed June 2026.
12. Civil Liability Act 1961, s.34 (apportionment for contributory negligence). irishstatutebook.ie. Accessed June 2026.
13. Gregg v Scott [2005] UKHL 2, House of Lords (England and Wales), contrasted with the Irish position in Philp v Ryan. bailii.org. Accessed June 2026.
14. High Court Practice Directions HC131 and HC132 (Clinical Negligence List), effective 28 April 2025. courts.ie. Accessed June 2026.
15. State Claims Agency, "Learning through Diagnosis Incident Reporting" (NIMS data 2022 to 2023; 79.2% delayed diagnosis, 52% reported at the test or investigation stage, 55% caused by a step not performed when indicated, with some test-stage incidents attributable to sampling errors). stateclaims.ie. Accessed June 2026.

This information is for educational purposes only and does not constitute legal advice. Every case is different and outcomes vary. The content reflects the law in the Republic of Ireland and does not apply to other jurisdictions. Gary Matthews Solicitors is regulated by the Law Society of Ireland. Consult a qualified solicitor for advice specific to your situation. In contentious business, a solicitor may not calculate fees or other charges as a percentage or proportion of any award or settlement.